- Home
- STTK vs WYY Comparison
STTK vs WYY Comparison
Compare STTK & WYY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- WYY
- Stock Information
- Founded
- STTK 2016
- WYY 1991
- Country
- STTK United States
- WYY United States
- Employees
- STTK N/A
- WYY N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- WYY EDP Services
- Sector
- STTK Health Care
- WYY Technology
- Exchange
- STTK Nasdaq
- WYY Nasdaq
- Market Cap
- STTK 36.2M
- WYY 35.6M
- IPO Year
- STTK 2020
- WYY 1998
- Fundamental
- Price
- STTK $0.84
- WYY $3.18
- Analyst Decision
- STTK Hold
- WYY Strong Buy
- Analyst Count
- STTK 4
- WYY 1
- Target Price
- STTK $3.00
- WYY $7.00
- AVG Volume (30 Days)
- STTK 305.5K
- WYY 36.2K
- Earning Date
- STTK 05-01-2025
- WYY 04-15-2025
- Dividend Yield
- STTK N/A
- WYY N/A
- EPS Growth
- STTK N/A
- WYY N/A
- EPS
- STTK N/A
- WYY N/A
- Revenue
- STTK $5,721,000.00
- WYY $142,571,749.00
- Revenue This Year
- STTK N/A
- WYY $7.92
- Revenue Next Year
- STTK N/A
- WYY $10.18
- P/E Ratio
- STTK N/A
- WYY N/A
- Revenue Growth
- STTK 245.26
- WYY 34.47
- 52 Week Low
- STTK $0.69
- WYY $1.83
- 52 Week High
- STTK $11.76
- WYY $6.25
- Technical
- Relative Strength Index (RSI)
- STTK 44.82
- WYY 51.09
- Support Level
- STTK $0.73
- WYY $2.50
- Resistance Level
- STTK $0.90
- WYY $3.35
- Average True Range (ATR)
- STTK 0.15
- WYY 0.47
- MACD
- STTK 0.00
- WYY 0.06
- Stochastic Oscillator
- STTK 19.96
- WYY 73.48
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About WYY WidePoint Corporation
WidePoint Corp is a provider of Technology Management as a Service (TMaaS) that consists of federally certified communications management, identity management, interactive bill presentment and analytics, and Information Technology as a Service solution. Its solutions include Telecom Lifecycle Management, Digital billing communications solutions, and Mobile and Identity management. Geographically the company generates a majority of its revenue from the United States and rest from Europe.